BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28837060)

  • 1. Synthesis and Characterization of Tissue Plasminogen Activator-Functionalized Superparamagnetic Iron Oxide Nanoparticles for Targeted Fibrin Clot Dissolution.
    Heid S; Unterweger H; Tietze R; Friedrich RP; Weigel B; Cicha I; Eberbeck D; Boccaccini AR; Alexiou C; Lyer S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
    Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
    Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery.
    Unterweger H; Tietze R; Janko C; Zaloga J; Lyer S; Dürr S; Taccardi N; Goudouri OM; Hoppe A; Eberbeck D; Schubert DW; Boccaccini AR; Alexiou C
    Int J Nanomedicine; 2014; 9():3659-76. PubMed ID: 25120363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue Plasminogen Activator Binding to Superparamagnetic Iron Oxide Nanoparticle-Covalent Versus Adsorptive Approach.
    Friedrich RP; Zaloga J; Schreiber E; Tóth IY; Tombácz E; Lyer S; Alexiou C
    Nanoscale Res Lett; 2016 Dec; 11(1):297. PubMed ID: 27299652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of potential iron oxide nanoparticles for breast cancer treatment based on in vitro cytotoxicity and cellular uptake.
    Poller JM; Zaloga J; Schreiber E; Unterweger H; Janko C; Radon P; Eberbeck D; Trahms L; Alexiou C; Friedrich RP
    Int J Nanomedicine; 2017; 12():3207-3220. PubMed ID: 28458541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypericin-bearing magnetic iron oxide nanoparticles for selective drug delivery in photodynamic therapy.
    Unterweger H; Subatzus D; Tietze R; Janko C; Poettler M; Stiegelschmitt A; Schuster M; Maake C; Boccaccini AR; Alexiou C
    Int J Nanomedicine; 2015; 10():6985-96. PubMed ID: 26648714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
    Chen HA; Ma YH; Hsu TY; Chen JP
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
    Tadayon A; Jamshidi R; Esmaeili A
    Int J Pharm; 2015 Nov; 495(1):428-438. PubMed ID: 26363110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermal and microwave synthesized SPIONs: Energy effects on the efficiency of nano drug carriers.
    Saxena N; Agraval H; Barick KC; Ray D; Aswal VK; Singh A; Yadav UCS; Dube CL
    Mater Sci Eng C Mater Biol Appl; 2020 Jun; 111():110792. PubMed ID: 32279785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo experiments with iron oxide nanoparticles functionalized with DEXTRAN or polyethylene glycol for medical applications: magnetic targeting.
    Mojica Pisciotti ML; Lima E; Vasquez Mansilla M; Tognoli VE; Troiani HE; Pasa AA; Creczynski-Pasa TB; Silva AH; Gurman P; Colombo L; Goya GF; Lamagna A; Zysler RD
    J Biomed Mater Res B Appl Biomater; 2014 May; 102(4):860-8. PubMed ID: 24458920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.
    Pernal SP; Willis AJ; Sabo ME; Moore LM; Olson ST; Morris SC; Creighton FM; Engelhard HH
    Int J Nanomedicine; 2020; 15():1549-1568. PubMed ID: 32210551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers.
    Wahajuddin ; Arora S
    Int J Nanomedicine; 2012; 7():3445-71. PubMed ID: 22848170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.
    Disharoon D; Trewyn BG; Herson PS; Marr DWM; Neeves KB
    J Thromb Haemost; 2022 Feb; 20(2):486-497. PubMed ID: 34882946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility.
    Zaloga J; Janko C; Nowak J; Matuszak J; Knaup S; Eberbeck D; Tietze R; Unterweger H; Friedrich RP; Duerr S; Heimke-Brinck R; Baum E; Cicha I; Dörje F; Odenbach S; Lyer S; Lee G; Alexiou C
    Int J Nanomedicine; 2014; 9():4847-66. PubMed ID: 25364244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges.
    Laurent S; Saei AA; Behzadi S; Panahifar A; Mahmoudi M
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1449-70. PubMed ID: 24870351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional polymeric nanoparticles doubly loaded with SPION and ceftiofur retain their physical and biological properties.
    Solar P; González G; Vilos C; Herrera N; Juica N; Moreno M; Simon F; Velásquez L
    J Nanobiotechnology; 2015 Feb; 13():14. PubMed ID: 25886018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient MRI labeling of endothelial progenitor cells: design of thiolated surface stabilized superparamagnetic iron oxide nanoparticles.
    Shahnaz G; Kremser C; Reinisch A; Vetter A; Laffleur F; Rahmat D; Iqbal J; Dünnhaupt S; Salvenmoser W; Tessadri R; Griesser U; Bernkop-Schnürch A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):346-55. PubMed ID: 23481176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent.
    Patil-Sen Y; Torino E; De Sarno F; Ponsiglione AM; Chhabria V; Ahmed W; Mercer T
    Nanotechnology; 2020 Sep; 31(37):375102. PubMed ID: 32392545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy.
    Huang Y; Yu L; Ren J; Gu B; Longstaff C; Hughes AD; Thom SA; Xu XY; Chen R
    J Control Release; 2019 Apr; 300():1-12. PubMed ID: 30807804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis.
    Zhou J; Guo D; Zhang Y; Wu W; Ran H; Wang Z
    ACS Appl Mater Interfaces; 2014 Apr; 6(8):5566-76. PubMed ID: 24693875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.